Literature DB >> 22945509

Molecular diagnosis of minimal residual disease in head and neck cancer patients.

A Peggy Graveland1, Boudewijn J M Braakhuis, Simone E J Eerenstein, Remco de Bree, Elisabeth Bloemena, Michiel de Maaker, Michiel W M van den Brekel, Frederike Dijk, Wilma E Mesker, Hans J Tanke, C Rene Leemans, Ruud H Brakenhoff.   

Abstract

AIM: Locoregional recurrences and distant metastases in adequately treated head and neck squamous cell carcinoma (HNSCC) patients have a dismal effect on survival. Tumor cells that escape histopathological detection might be the prime cause of this effect. We evaluated whether minimal residual cancer (MRC) in deep surgical margins and disseminated tumor cells (DTCs) in bone marrow aspirates are associated with clinicohistopathological parameters and outcome.
METHODS: Submucosal samples of deep resection margins of 105 HNSCC patients with histopathologically tumor-free surgical margins were analysed for the presence of MRC using hLy-6D qRT-PCR. Bone-marrow aspirates of 76 of these patients were analysed for DTCs by immunocytochemical staining. Presence of molecular-positive deep surgical margins, presence of DTC in bone marrow aspirates, and clinicohistopathological parameters were tested for associations with survival parameters by univariate and multivariate analyses.
RESULTS: In addition to lymph node stage, it appeared that vasoinvasive growth and particularly infiltrative growth pattern are significant predictors for locoregional recurrence (p = 0.041 and p = 0.006, respectively) and disease-free survival (p = 0.014 and p = 0.008, respectively). Remarkably, neither the presence of molecular-positive deep surgical margins nor that of DTC in bone marrow aspirates were significantly related to outcome.
CONCLUSIONS: The presence of vasoinvasive and infiltrative growth in HNSCC tumor specimens are significant risk-factors for locoregional recurrence and disease-free survival. At present there seems no role for molecular analysis of deep surgical margins and bone marrow aspirates in predicting outcome with the methods used.

Entities:  

Mesh:

Year:  2012        PMID: 22945509     DOI: 10.1007/s13402-012-0097-1

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  35 in total

1.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients.

Authors:  Waseem Jerjes; Tahwinder Upile; Aviva Petrie; Andrew Riskalla; Zaid Hamdoon; Michael Vourvachis; Kostas Karavidas; Amrita Jay; Ann Sandison; Gareth J Thomas; Nicholas Kalavrezos; Colin Hopper
Journal:  Head Neck Oncol       Date:  2010-04-20

2.  Clinical relevance of occult tumor cells in lymph nodes from gastric cancer patients.

Authors:  Fania S Doekhie; Wilma E Mesker; J Han J M van Krieken; Niels F M Kok; Henk H Hartgrink; Elma Klein Kranenbarg; Hein Putter; Peter J K Kuppen; Hans J Tanke; Rob A E M Tollenaar; Cornelis J H van de Velde
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

3.  An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts.

Authors:  O R Merino; R D Lindberg; G H Fletcher
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

4.  Metastatic patterns in squamous cell cancer of the head and neck.

Authors:  C Kotwall; K Sako; M S Razack; U Rao; V Bakamjian; D P Shedd
Journal:  Am J Surg       Date:  1987-10       Impact factor: 2.565

Review 5.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma.

Authors:  A Peggy Graveland; Pawel J Golusinski; Marijke Buijze; Rinze Douma; Nanet Sons; Dirk J Kuik; Elisabeth Bloemena; C René Leemans; Ruud H Brakenhoff; Boudewijn J M Braakhuis
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

7.  Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays.

Authors:  S Löseke; E Grage-Griebenow; A Wagner; K Gehlhar; A Bufe
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

8.  Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction.

Authors:  Eline J C Nieuwenhuis; C René Leemans; J Alain Kummer; Fedor Denkers; Gordon B Snow; Ruud H Brakenhoff; Alain Kummer
Journal:  Lab Invest       Date:  2003-08       Impact factor: 5.662

9.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.

Authors:  K Pantel; G Schlimok; M Angstwurm; D Weckermann; W Schmaus; H Gath; B Passlick; J R Izbicki; G Riethmüller
Journal:  J Hematother       Date:  1994

10.  Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients.

Authors:  A Peggy Graveland; Michiel de Maaker; Boudewijn J M Braakhuis; Remco de Bree; Simone E J Eerenstein; Elisabeth Bloemena; C René Leemans; Ruud H Brakenhoff
Journal:  Cell Oncol       Date:  2009       Impact factor: 6.730

View more
  6 in total

1.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Authors:  Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

Review 2.  Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.

Authors:  Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-07       Impact factor: 2.503

Review 3.  Squamous cell carcinoma of the oral cavity and circulating tumour cells.

Authors:  Johannes Wikner; Alexander Gröbe; Klaus Pantel; Sabine Riethdorf
Journal:  World J Clin Oncol       Date:  2014-05-10

4.  Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.

Authors:  Maria J De Herdt; Stefan M Willems; Berdine van der Steen; Rob Noorlag; Esther I Verhoef; Geert J L H van Leenders; Robert J J van Es; Senada KoljenoviÄ; Robert J Baatenburg de Jong; Leendert H J Looijenga
Journal:  Oncotarget       Date:  2016-03-15

Review 5.  Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.

Authors:  Wang Gong; Yandi Xiao; Zihao Wei; Yao Yuan; Min Qiu; Chongkui Sun; Xin Zeng; Xinhua Liang; Mingye Feng; Qianming Chen
Journal:  Oncotarget       Date:  2017-01-10

6.  Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.

Authors:  Joost H van Ginkel; Wendy W J de Leng; Remco de Bree; Robert J J van Es; Stefan M Willems
Journal:  Oncotarget       Date:  2016-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.